Drugs / Dextromethorphan/quinidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03854019 | Aug 2019 → Nov 2022 | Huntington disease | The University of Texas Health Science Center, Houston | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dextromethorphan/quinidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03854019 ↗ |
| Known as | DM/Q | “Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg)” NCT03854019 ↗ |